证券代码：002932 证券简称：明德生物 公告编号：2026-016 武汉明德生物科技股份有限公司 关于首次回购公司股份暨回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 武汉明德生物科技股份有限公司（以下简称"公司"）于 2026 年 3 月 23 日召开第五届董事会第四次会议，审议通过了《关于回购公司股份方案的议案》， 拟使用自有资金或自筹资金以集中竞价方式回购公司股份，拟用于维护公司价值 及股东权益，本次回购的股份后续将按有关规定予以全部出售。回购资金总额不 高于人民币 20,000.00 万元、不低于人民币 10,000.00 万元，回购价格不超过人民 币 28 元/股，具体回购股份数量以回购届满时实际回购的股份数量为准。本次回 购股份实施期限为自公司董事会审议通过回购股份方案之日起 3 个月内。具体内 容 详 见 公 司 于 2026 年 3 月 24 日 刊 登 在 《 证 券 时 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）的《关于回购公司股份方案的公告暨回购报告书》 （公告编号：2026- ...

Market News - The National Bureau of Statistics will release the March PMI data on March 31, 2026, with the February manufacturing PMI at 49.0%, a decrease of 0.3 percentage points month-on-month, and the non-manufacturing business activity index at 49.5%, an increase of 0.1 percentage points from the previous month [3] - The export tax rebate for photovoltaic and some products will be officially canceled starting April 1, 2026, aimed at guiding industrial transformation and upgrading, and addressing changes in the international trade environment [4] - China will implement a preferential tariff rate on certain imported goods originating from the Republic of Congo starting April 1, 2026, to deepen economic and trade cooperation with Africa [5] - Geopolitical fluctuations are increasing volatility in global risk assets, with international oil prices showing an upward trend since late February, significantly impacting global liquidity and inflation expectations [6] - The central bank will continue to implement a moderately loose monetary policy in 2026, planning to lower the interest rates of various structural monetary policy tools by 0.25 percentage points to support the start of the "14th Five-Year Plan" [7] Sector Matters - The semiconductor storage sector is gaining attention as the domestic SSD leader, Dapu Micro, plans to open subscriptions this week, with expectations of explosive growth in the enterprise SSD market due to increasing demand from AI models [9] - The photovoltaic sector is experiencing price fluctuations due to the upcoming cancellation of export tax rebates, which is expected to increase export costs by approximately 13% [10] - Domestic airlines, including Spring Airlines, will raise fuel surcharges for domestic flights starting April 5, 2026, in response to rising international oil prices [11] - The application fields for metal composite materials are expanding, driven by demand from high-end equipment manufacturing [13] - The energy sector is showing strong resilience, with rising oil prices boosting the valuation of oil and gas extraction companies [14] Individual Company News - China Petroleum reported a 4.5% year-on-year decline in net profit for 2025, with a proposed cash dividend of 0.25 yuan per share [16] - Mingde Biology plans to acquire 100% of Wuhan Bikaier's equity in cash, which will become a wholly-owned subsidiary [17] - Tianshan Aluminum expects a 107.92% year-on-year increase in net profit for the first quarter of 2026 [18] - Sanor Bio plans to repurchase shares worth between 150 million and 300 million yuan [19] - Nanjing Panda reported a net profit of 11 million yuan for 2025, marking a turnaround from losses [20] Lock-up Expiration - A total of 29 companies will have lock-up shares released this week, amounting to 1.334 billion shares with a total market value of approximately 37.488 billion yuan [22] - The peak lock-up expiration date is March 30, with 16 companies releasing shares worth a total of 31.962 billion yuan, accounting for 85.26% of the week's total [22] New Stock Calendar - Three new stocks will be issued this week, including Youyan Composite on March 30, Saiying Electronics on March 30, and Dapu Micro on April 3 [26] Institutional Outlook - CITIC Securities suggests maintaining a focus on China's advantageous manufacturing sectors while awaiting April's decisive policies [29] - Guosen Securities remains optimistic about the market despite recent adjustments, viewing them as normal technical corrections in the early stages of a bull market [30] - Dongwu Securities highlights geopolitical risks as a core pricing factor, recommending a balanced investment approach [32]

证券代码：002932 证券简称：明德生物 公告编号：2026-015 武汉明德生物科技股份有限公司 关于重大资产重组进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日披露了《关于筹划重大资产重组暨签署<股权收购意向协议>的提示性公告》 （公告编号：2025-056），已对本次交易涉及的相关事项进行了说明。 四、风险提示 截至本次公告披露日，公司就本次交易事项同各相关方持续沟通协商，并积 极推进审计、评估及尽职调查等相关工作。本次交易相关方尚未签署正式交易文 件，公司将根据本次交易的进展情况，严格按照相关法律法规的规定履行有关的 决策审批程序和信息披露义务。 一、交易概述 公司拟以现金方式收购蓝帆医疗股份有限公司持有的武汉必凯尔救助用品 有限公司（以下简称"标的公司"）100%股权。本次交易完成后，标的公司将 成为公司的全资子公司。本次交易预计构成《上市公司重大资产重组管理办法》 规定的重大资产重组。本次交易拟采用现金方式，不构成重组上市，不涉及上市 ...

证券代码：002932 证券简称：明德生物 公告编号：2026-014 武汉明德生物科技股份有限公司 关于回购股份事项前十名股东及前十名无限售条件股东 持股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 武汉明德生物科技股份有限公司（以下简称"公司"）于 2026 年 3 月 23 日召开了第五届董事会第四次会议，审议通过了《关于回购公司股份方案的议 案》，具体内容详见公司于 2026 年 3 月 24 日刊登在《证券时报》及巨潮资讯网 （http://www.cninfo.com.cn）的《关于回购公司股份方案的公告暨回购报告书》 （公告编号：2026-013）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，现将公司董事会公告回购股份决议前一个交易 日（即 2026 年 3 月 23 日）登记在册的前十大股东和前十大无限售条件股东的名 称及持股数量、比例公告如下： 二、董事会公告回购股份决议前一交易日（即 2026 年 3 月 23 日）登记在 册的前十名无限售条件股东持股情况 | 序号 | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、回购方案主要内容： 证券代码：002932 证券简称：明德生物 公告编号：2026-013 武汉明德生物科技股份有限公司 关于回购公司股份方案的公告 暨回购报告书 武汉明德生物科技股份有限公司（以下简称"公司"、"本公司"）本次将 以集中竞价交易方式回购公司股份，回购股份的资金总额不超过（含）人民币 20,000 万元且不低于（含）人民币 10,000 万元；回购股份种类为公司已发行的 人民币普通股（A 股）股票；回购股份价格不超过（含）人民币 28 元/股，按此 次回购资金最高人民币 20,000 万元测算，预计可回购股份数量为 714.2857 万股， 约占公司目前总股本的 3.07%；按此次回购资金最低人民币 10,000 万元测算，预 计可回购股份数量为 357.1429 万股，约占公司目前总股本的 1.54%。回购期限自 董事会审议通过回购股份方案之日起不超过三个月，具体回购数量及回购金额以 回购期满或回购完毕时实际回购的股份数量和回购金额为准，回购股份用于维护 公司价值及股东权益。 ...

证券代码：002932 证券简称：明德生物 公告编号：2026-012 武汉明德生物科技股份有限公司 第五届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉明德生物科技股份有限公司（以下简称"公司"）第五届董事会第四次 会议于 2026 年 3 月 23 日以现场结合通讯方式召开，会议通知已于 2026 年 3 月 19 日以电子邮件、电话通讯等形式发出。本次会议应到董事 8 名，实际出席公 司会议的董事 8 名，会议由董事长陈莉莉女士主持，公司高级管理人员列席了本 次会议，会议的召集和召开符合《中华人民共和国公司法》等法律法规及《公司 章程》的规定。 二、董事会会议审议情况 逐项审议并通过《关于回购公司股份方案的议案》 （一）回购股份的目的 基于对公司未来发展前景的信心以及对公司价值的高度认可，为维护广大投 资者的利益，增强投资者信心，公司拟通过集中竞价方式进行股份回购，回购的 公司股份拟用于维护公司价值及股东权益。 本次回购的股份将在披露回购结果暨股份变动公告 12 个月后根据相关规则 择机采用集中竞价 ...

Core Viewpoint - Mingde Biological's stock price plummeted due to a sudden revision of its 2025 performance forecast, indicating a significant shift from previous expectations [3][4]. Group 1: Performance Forecast Revision - Mingde Biological announced a revised forecast for 2025, expecting a net loss attributable to shareholders of between 15 million to 25 million yuan, with a net loss excluding non-recurring gains and losses projected at 100 million to 140 million yuan [3][4]. - This revision contrasts sharply with the earlier forecast made on January 30, which estimated a net profit of approximately 12 million to 18 million yuan, and a net loss excluding non-recurring items of about 78 million to 98 million yuan [3][4]. Group 2: Risk of Delisting - The company may face a risk warning for delisting, as it anticipates negative values for total profit, net profit, and net profit excluding non-recurring gains and losses, with revenue expected to fall below 300 million yuan [4][5]. Group 3: Factors Behind Performance Decline - The decline in performance is attributed to slow collection of accounts receivable, leading to a cautious approach in revenue recognition [5]. - The company is conducting impairment tests on assets showing signs of impairment, which has further adjusted the net profit downward [5]. - Factors impacting performance include bad debt losses from accounts receivable, reduced government subsidies, and profit compression due to centralized procurement in the in vitro diagnostic reagent industry [5]. Group 4: Accounts Receivable Situation - As of the first three quarters of 2025, Mingde Biological's accounts receivable stood at 653 million yuan, approximately 2.88 times the company's revenue [6].

Group 1 - Premier Li Qiang emphasized that China's competitive advantages come from deepening reforms and innovation, not subsidies or protectionism, and highlighted the importance of fair competition in the market economy [4] - Central Bank Governor Pan Gongsheng stated that the People's Bank of China will maintain a supportive monetary policy stance to create a favorable environment for stable economic growth and high-quality development [4] - The National Internet Emergency Center and the China Cybersecurity Association released security guidelines for the use of OpenClaw, providing recommendations for ordinary users and cloud service providers [5] Group 2 - The China Development Forum 2026 released multiple policy signals, indicating a focus on high-quality development and global economic stability [6] - The Chinese automotive industry achieved a significant milestone by surpassing Japan in global annual sales for the first time, with nearly 27 million vehicles sold [17] - The Ministry of Finance plans to increase public service spending and implement consumer-friendly policies to stimulate domestic demand, including a special fund of 100 billion yuan to promote consumption [9][10] Group 3 - The latest findings from the Ministry of Natural Resources revealed a significant increase in rare earth resources in Sichuan, with verified reserves totaling 9.67 million tons, marking an over 200% increase compared to previous estimates [18] - The launch of the "TERAFAB" chip manufacturing project by Tesla aims to achieve an annual production capacity of over 1 terawatt, with an estimated total investment of $20 billion [21] - Apple CEO Tim Cook announced continued support for innovation and education in China, pledging additional donations to a national vocational education pilot project [22]

Core Viewpoint - Mingde Biological (002932) is expected to face a significant loss in 2025, with a projected total profit loss of 50 million to 75 million yuan and a net profit loss attributable to shareholders of 15 million to 25 million yuan, leading to a potential delisting risk warning from the Shenzhen Stock Exchange [1][2]. Financial Performance Summary - The revised total profit for 2025 is projected to be a loss of 50 million to 75 million yuan, compared to a profit of 32.416 million yuan in the previous year [2]. - The net profit attributable to shareholders is now expected to be a loss of 15 million to 25 million yuan, revised from a previous estimate of a profit of 12 million to 18 million yuan [2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 100 million to 140 million yuan, indicating a significant downward revision [2][3]. - The expected operating revenue for 2025 is estimated to be between 25 million and 31 million yuan, down from 350.0618 million yuan in the previous year [2]. - The adjusted operating revenue, after deductions, is projected to be between 23.7 million and 29.7 million yuan, also a decrease from 348.4858 million yuan in the previous year [2]. Reasons for Performance Revision - The company conducted a comprehensive review and cautious analysis of its operating revenue, deciding not to recognize certain revenues due to significant uncertainty regarding accounts receivable collections [3]. - Further communication with the annual audit accounting firm led to impairment testing of assets showing signs of impairment, resulting in adjustments to asset impairment loss amounts, which negatively impacted the net profit attributable to shareholders [4]. Company Operations Status - The company stated that its production and operations are currently normal and expressed sincere apologies for any inconvenience caused to investors by the performance forecast revision [5].

证券代码：002932 证券简称：明德生物 公告编号：2026-011 武汉明德生物科技股份有限公司 关于公司股票交易可能被实施退市风险警示的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 武汉明德生物科技股份有限公司（以下简称"公司"）预计 2025 年度经审 计后的利润总额、净利润、扣除非经常性损益后的净利润为负值，且扣除后的营 业收入低于 3 亿元。根据《深圳证券交易所股票上市规则》第 9.3.1 条第一款第 （一）项规定，公司股票交易可能在 2025 年年度报告披露后被深圳证券交易所 实施退市风险警示（股票简称前冠以"*ST"字样）。敬请广大投资者注意投资 风险。 一、公司股票交易可能被实施退市风险警示的原因 经公司财务部门初步测算（未经审计），预计公司 2025 年度利润总额为亏 损 5,000 万元至 7,500 万元，归属于上市公司股东的净利润为亏损 1,500 万元至 2,500 万元，归属于上市公司股东的扣除非经常性损益后的净利润为亏损 10,000 万元至 14,000 万元，预计营业收入为 25,000 万元至 3 ...